Kronik Hepatit B Virüs enfeksiyonu olan hastalarda Hepatit A Virüs seroprevalansı

Abstract

Objective: The aim of this study was to retrospectively investigate Hepatitis A seroprevalence in patients with chronic hepatitis B and to vaccinate susceptible individuals. Material and Methods: Between November 2018 and November 2019, HAV Ab-IgG results of patients with chronic hepatitis B admitted to hospital infectious diseases outpatient clinic were evaluated. The HAVAb-IgG assay was investigated on the ARCHITECT i2000SR analyzer with the ARCHITECT® HAVAb-IgG assayusing the Chemiluminescent Microparticle Immunoassay (CMIA) method. Statistical analysis of the data was analyzed using the Statistical Packagefor Social Sciences 21 statistical package program. Results: 138 patients with chronic hepatitis B were evaluated. HAV Ab-IgG was not performed in 27 patients. 111 patients were included in the study. 64 (57.7%) of the patients were female and 47 (42.3%) were male. The patients were between the ages of 15-84. The mean age was 48.01 ± 11.86 years. Anti-HAV IgG was positive in 105 (94.6%) patients and negative in 6 (5.4%) patients. The mean age of anti-HAV IgG positive patients was 49.25 ± 11.31 years. Of the patients with anti-HAV IgG negative, 2 (33.3%) were female and 4 (66.7%) were male. The patients were between 15-36 years old. The mean age was 26.16 ± 5.16 years. Conclusion: Seroprevalence of hepatitis A virus was 94.6% in patients with chronic hepatitis B virus infection. HAV Ab-IgG should be tested in patients with HBV infection and patients who are anti-HAV IgG negative should be included in the vaccination program.